Form 4: Catalyst Pharmaceuticals Executive Ingenito Reports Stock Transactions

Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.

Summary

• Gary Ingenito, Chief Medical & Regulatory Officer of Catalyst Pharmaceuticals, filed a Form 4 on February 19, 2025.
• The report details transactions related to restricted stock units (RSUs) that vested on February 14, 2025.
• Ingenito acquired 10,000 shares of common stock upon the vesting of these RSUs.
• 2,435 shares were withheld by Catalyst Pharmaceuticals to satisfy applicable withholding taxes.
• Following these transactions, Ingenito directly owns 68,873 shares of Catalyst Pharmaceuticals common stock.
• Ingenito also directly owns 1,015,282 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The vesting of RSUs and subsequent tax withholding has a minor dilutive effect on existing shareholders.

Key Dates